Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19138367 | 0.89 | CAPN1 (0.62) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| SCHEMBL19138278 | 0.89 | CAPN1 (0.62) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| SCHEMBL19138277 | 0.89 | CAPN1 (0.62) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| SCHEMBL19138299 | 0.89 | CAPN1 (0.62) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| Rapastinel SCHEMBL23859841 | 0.88 | CAPN1 (0.59) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| Rapastinel SCHEMBL23753673 | 0.88 | CAPN1 (0.59) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| Rapastinel SCHEMBL20814039 | 0.88 | CAPN1 (0.59) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| Rapastinel SCHEMBL25266713 | 0.88 | CAPN1 (0.59) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| Rapastinel SCHEMBL20678315 | 0.88 | CAPN1 (0.59) | CAPN1CTSBXIAPSLC6A2GRB2 | |
| Rapastinel SCHEMBL21549060 | 0.88 | CAPN1 (0.59) | CAPN1CTSBXIAPSLC6A2GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590167-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | NAUREX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180127466-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9745342-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | NAUREX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160244485-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015065891-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590167-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | GRIN1, GRIN3A, GRIN2A | CAPN1 519/4885CTSB 3295/4885XIAP 3194/4885 |
| US-20180127466-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | GRIN1, GRIN3A, GRIN2A | CAPN1 519/4885CTSB 3295/4885XIAP 3194/4885 |
| US-20160244485-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CAPN1 197/4885CTSB 4360/4885XIAP 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.